Core Viewpoint - The article discusses the development of receptor-ubiquitination-targeting antibody-drug conjugates (ubitaADC) that enhance endocytosis and lysosomal delivery, thereby improving anti-tumor efficacy [4][9]. Group 1: Mechanism and Challenges - Antibody-drug conjugates (ADCs) are a new class of targeted cancer therapies that rely on antibody-mediated receptor binding, internalization, and lysosomal processing to deliver cytotoxic drugs to tumor cells [2]. - The efficacy of ADCs is often limited by biological constraints related to receptor fate, including low internalization efficiency and restricted lysosomal transport [3]. Group 2: Research Findings - The research team from Zhejiang University developed ubitaADC, which enhances endocytosis and lysosomal delivery, applicable to various receptors and allowing modular design for improved ADC performance [4][11]. - The study established receptor ubiquitination as a programmable mechanism to actively control receptor transport in ADC therapy, combining antibody targeting with selective recruitment of membrane-associated E3 ubiquitin ligases [7]. Group 3: Experimental Results - Using EGFR and HER2 targeting systems, the strategy demonstrated improved delivery of cytotoxic payloads and enhanced tumor-killing effects in colorectal cancer models, even in cases of acquired resistance to traditional antibodies [7]. - In vivo, ubitaADC exhibited superior anti-tumor efficacy compared to traditional ADCs [7]. Group 4: Implications and Future Directions - The research redefines receptor ubiquitination as a design principle for enhancing ADC performance, expanding the toolbox for manipulating cancer cell receptor fate and indicating opportunities to combine targeted protein regulation with next-generation drug conjugation technologies [9].